GURU.Markets stock price, segment price, and overall market index valuation
The company's share price DNLI
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases such as Parkinson's and Alzheimer's. Its stock price reflects the enormous potential and high risks associated with developing drugs for these complex conditions.
Share prices of companies in the market segment - Neuro
Denali is a biotech company specializing in the treatment of neurodegenerative diseases such as Parkinson's disease. We classify it in the Neuro sector, and the chart below shows the overall performance of biotech companies, where value is driven by the success of its unique blood-brain barrier-crossing technology.
Broad Market Index - GURU.Markets
Denali Therapeutics is a biotech company focused on developing drugs to treat neurodegenerative diseases by crossing the blood-brain barrier. It is a component of the GURU.Markets index. The chart below represents the market. See how Denali shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
DNLI - Daily change in the company's share price DNLI
Denali, a company focused on treating neurodegenerative diseases, is highly volatile. change_co tracks market reactions to research data. This metric is fundamental for building complex biotech risk assessment models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Denali Therapeutics Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with DNLI, which focuses on neurodegenerative diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Denali is a biopharmaceutical company specializing in drugs for the treatment of neurodegenerative diseases. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Denali's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization DNLI
Denali is a biotech company specializing in the treatment of neurodegenerative diseases. Its year-over-year performance reflects both the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Neuro
Denali Therapeutics Inc. is a biotech company focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. Its unique blood-brain barrier-crossing technology is a key advantage. The chart below shows how the market views its scientific potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Denali Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization DNLI
Denali, a biotech company focused on breaking the blood-brain barrier to treat neurodegenerative diseases, has sharp monthly fluctuations reflecting news about clinical trials of its innovative platform.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the biotech sector. For Denali, with its focus on breaking the blood-brain barrier, it's the backdrop. Its movements demonstrate how investor expectations surrounding its unique technology platform influence its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Denali Therapeutics develops drugs to treat neurodegenerative diseases. This is one of the most complex areas in biotech, and the company's shares move in sync with clinical trial news. Its monthly performance is almost entirely independent of the market, representing a risky bet on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization DNLI
Denali Therapeutics Inc. is a biotech company focused on treating neurodegenerative diseases such as Parkinson's and Alzheimer's. Its weekly stock price is driven by news about clinical trials of its drugs, which use technology to cross the blood-brain barrier.
Weekly dynamics of market capitalization of the market segment - Neuro
Denali, with its unique brain drug delivery technology, is on its own trajectory, separate from the broader biotech sector. News about its platform and partnerships are its main drivers. The chart clearly shows how its breakthrough science is giving its stock a life of its own, independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Denali Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases. Its shares are a bet on a scientific breakthrough. The chart clearly shows their extreme volatility and complete dependence on news about clinical trials.
Market capitalization of the company, segment and market as a whole
DNLI - Market capitalization of the company DNLI
Denali Therapeutics' market capitalization reflects investor hopes for its scientific platform, designed to cross the blood-brain barrier and deliver drugs to the brain. Its volatile price chart reflects how the market perceives its potential to treat neurodegenerative diseases such as Parkinson's and Alzheimer's.
DNLI - Share of the company's market capitalization DNLI within the market segment - Neuro
Denali Therapeutics Inc. is a biotechnology company focused on crossing the blood-brain barrier to treat neurodegenerative diseases. Its market share reflects the potential of its unique technology platform.
Market capitalization of the market segment - Neuro
Below is a chart of the total market capitalization of the biotech sector. Denali Therapeutics is a leader in the highly complex field of brain drug development. The company has developed a technology for "transport across the blood-brain barrier." The potential of this market is enormous, and Denali is at the forefront of research in the fight against Alzheimer's and Parkinson's.
Market capitalization of all companies included in a broad market index - GURU.Markets
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases like Alzheimer's. Its market cap represents the hope of a breakthrough in one of the most challenging areas of medicine. The chart below illustrates the weight of this hope.
Book value capitalization of the company, segment and market as a whole
DNLI - Book value capitalization of the company DNLI
Denali Therapeutics' foundation is its scientific platform, specifically its "vehicle" technology for delivering drugs across the blood-brain barrier to treat neurodegenerative diseases. This chart tells the story of a biotech company investing in solving one of the most complex problems in medicine, which requires significant capital.
DNLI - Share of the company's book capitalization DNLI within the market segment - Neuro
Denali Therapeutics develops drugs to treat neurodegenerative diseases. The chart shows its share of actual R&D assets. These are its laboratories, where they fight Alzheimer's and Parkinson's diseases using a unique technology for delivering drugs to the brain.
Market segment balance sheet capitalization - Neuro
Denali Therapeutics is a biotech focused on neurodegenerative diseases. Its model is intellectually, not capital-intensive. Its value lies in its scientific platform for crossing the blood-brain barrier, not in its manufacturing facilities. Compared to the pharmaceutical sector, its "light" balance sheet is typical of R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
Denali's assets represent scientific capital focused on solving one of the most complex challenges in medicine: delivering drugs across the blood-brain barrier to treat brain diseases. The company's balance sheet reflects the value of its unique technology. The chart shows the amount of resources invested in the fight against Alzheimer's and Parkinson's.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - DNLI
Denali Therapeutics is a neuroscience company developing treatments for Alzheimer's and Parkinson's diseases. Its market value is derived from its unique technology for crossing the blood-brain barrier. Investors are buying into the hope of a breakthrough in one of the most complex areas of medicine.
Market to book capitalization ratio in a market segment - Neuro
Denali Therapeutics develops drugs to treat neurodegenerative diseases. Its key advantage is its unique technology for delivering drugs to the brain. This chart shows the enormous premium investors are paying for this breakthrough platform, not just lab equipment.
Market to book capitalization ratio for the market as a whole
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases such as Parkinson's and Alzheimer's. Its market capitalization is based on the potential of its scientific platform. The chart shows the enormous premium investors are paying for research in one of the most complex areas of medicine.
Debts of the company, segment and market as a whole
DNLI - Company debts DNLI
Denali Therapeutics is a neuroscience company developing treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's. Its unique blood-brain barrier-crossing technology requires significant investment in research, as reflected in its financial strategy, shown in this chart.
Market segment debts - Neuro
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases such as Alzheimer's and Parkinson's. This is one of the most complex and expensive areas in medicine. This chart shows how the company funds its ambitious and long-term research and how its partnerships with major pharma companies influence its financial structure.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio DNLI
Denali Therapeutics is a biotech company specializing in developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. This chart shows its financial structure. The lack of debt and reliance on equity and large partnerships are essential to funding its breakthrough, yet highly risky, research.
Market segment debt to market segment book capitalization - Neuro
Denali Therapeutics is a neuroscience company developing drugs to treat neurodegenerative diseases. The chart reflects the debt burden in a sector where scientific breakthroughs require huge and risky investments. It helps understand how Denali's financial model compares to the long lead times and high costs of development in this complex field.
Debt to book value of all companies in the market
Denali Therapeutics, a neuroscience company, requires massive investments in R&D. The chart reflects debt trends across the economy. It serves as a reminder that while the market as a whole is driven by debt, companies at the forefront of science, like Denali, manage scientific risk, and their funding depends on faith in future discoveries.
P/E of the company, segment and market as a whole
P/E - DNLI
For Denali Therapeutics, which focuses on treating neurodegenerative diseases, this chart represents a bet on a breakthrough in one of the most complex areas of medicine. The potential profit is highly valued, as investors see a huge market for Alzheimer's and Parkinson's drugs. The trend reflects clinical trial data.
P/E of the market segment - Neuro
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Denali. For investors, it's a benchmark indicating the overall level of optimism in the field of neurodegenerative disease treatments. Against this backdrop, one can gauge expectations for Denali's unique technology for crossing the blood-brain barrier.
P/E of the market as a whole
Denali Therapeutics develops drugs to treat neurodegenerative diseases such as Parkinson's and Alzheimer's by attempting to overcome the blood-brain barrier. This chart of biotech investor risk appetite demonstrates their willingness to invest in one of the most complex areas of medicine, where the risks of failure are very high, but the potential rewards are also enormous.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company DNLI
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its valuation is based on the potential of its scientific platform. This chart demonstrates analysts' confidence in the company's ability to cross the blood-brain barrier and develop effective treatments.
%20P%2FE%20DNLI&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-DNLI&v=1772548201738 "Chart of the company's future (projected) P/E DNLI")
Future (projected) P/E of the market segment - Neuro
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Its valuation relative to other biotechs reflects investor hopes for its unique blood-brain barrier-crossing technology. This is a bet on a breakthrough in one of the most challenging areas of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772548201804 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. This is one of the most complex areas in medicine. This chart shows the overall risk appetite of investors. For companies working on breakthrough but highly risky projects, a positive market environment is essential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772548201902 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit DNLI
Denali Therapeutics is a neuroscience company focused on developing treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's. Its financial performance, reflected here, reflects investments in breakthrough science, including blood-brain barrier-crossing technology.
Profit of companies in the market segment - Neuro
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart reflects the financial health of the neuroscience segment of the biotech company, demonstrating how close this highly complex field of medicine is to breakthroughs and commercial success.
Overall market profit
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases such as Parkinson's and Alzheimer's. Its primary goal is to overcome the blood-brain barrier to deliver drugs to the brain. DNLI's success depends on scientific breakthroughs, not the state of corporate profits shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company DNLI
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its key goal is to overcome the blood-brain barrier. Its earnings forecast reflects analysts' confidence in its scientific platform and the potential to create breakthrough treatments in this complex area.
%20profit%20of%20the%20company%20DNLI&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-DNLI&v=1772548202074 "Graph of future (projected) profit of the company DNLI")
Future (predicted) profit of companies in the market segment - Neuro
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases such as Parkinson's, Alzheimer's, and ALS. Their key technology helps their drugs cross the blood-brain barrier. This chart shows forecasts for the neurosegment, illustrating the enormous expectations for breakthroughs in the treatment of these complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772548202079 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Denali Therapeutics is a biopharmaceutical company focused on treating neurodegenerative diseases. This projected profit curve is impacting the biotech investment climate. Market optimism and economic growth are facilitating the raising of the significant capital needed to conduct long-term and complex clinical trials in brain diseases.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772548202087 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - DNLI
Denali Therapeutics is a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer's. This metric reflects investors' assessment of its scientific platform and potential future revenue, despite the lack of commercial products.
P/S market segment - Neuro
Denali Therapeutics is a neuroscience company focused on developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. This chart shows the average valuation in the neuroscience sector. It reflects investor expectations for Denali's innovative platform, which is capable of delivering drugs across the blood-brain barrier.
P/S of the market as a whole
Denali Therapeutics Inc. is a biotech company focused on developing drugs for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its core value lies in its scientific platform. Future revenue depends on breakthroughs in this complex field. This chart helps put into perspective the enormous expectations investors have for the biotech company.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company DNLI
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases such as Parkinson's and Alzheimer's. Its future revenue depends on the success of its blood-brain barrier-crossing platform. The chart reflects investor confidence in the breakthrough potential of its scientific developments.
%20P%2FS%20DNLI&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-DNLI&v=1772548202166 "The graph of the company's future (projected) P/S DNLI")
Future (projected) P/S of the market segment - Neuro
Denali Therapeutics is a neuroscience company developing drugs to treat neurodegenerative diseases such as Parkinson's, Alzheimer's, and ALS. Its core technology helps its drugs cross the blood-brain barrier. This chart shows how investors view the potential of its scientific platform compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772548202178 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This chart illustrates investor sentiment in the field of brain disease treatment. For Denali Therapeutics, a biotech company focused on neurodegenerative diseases, it reflects faith in science. Market optimism is essential for funding breakthrough research aimed at fighting Alzheimer's and Parkinson's diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772548202204 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales DNLI
Denali Therapeutics is a biotech company focused on developing drugs to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. This chart shows revenue from partnerships with major pharmaceutical companies. Its growth will depend on the success of clinical trials of drugs capable of crossing the blood-brain barrier.
Sales of companies in the market segment - Neuro
Denali Therapeutics is a biotech company focused on developing drugs to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. This chart shows growth in the neuroscience sector. Denali has developed a technology for delivering large molecules across the blood-brain barrier, which could be a breakthrough for the entire industry.
Overall market sales
Denali Therapeutics Inc. is a biotech company focused on treating neurodegenerative diseases such as Parkinson's and Alzheimer's. Its development depends on success in clinical trials. The overall economic situation, shown in this chart, influences investment in the capital-intensive biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company DNLI
Denali Therapeutics is a neuroscience company focused on developing drugs to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. Its core technology helps its drugs cross the blood-brain barrier. This chart reflects analysts' belief in the breakthrough potential of Denali's platform in one of the most challenging areas of medicine.
%20sales%20of%20the%20company%20DNLI&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-DNLI&v=1772548202278 "Schedule of future (projected) sales of the company DNLI")
Future (projected) sales of companies in the market segment - Neuro
Denali Therapeutics is a biotech company focused on developing treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's. The forecast highlights expectations for the neuroscience pharmaceutical segment, reflecting the enormous unmet need for effective treatments for these devastating diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772548202293 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Denali Therapeutics Inc. is a biotech company focused on developing drugs to treat neurodegenerative diseases such as Parkinson's and Alzheimer's. Its valuation depends on research breakthroughs. This graph, reflecting the state of the economy, affects the availability of capital for long-term, high-risk biotech research projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772548202342 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality DNLI
Denali Therapeutics is a biotech company focused on the challenging task of treating neurodegenerative diseases such as Alzheimer's. The chart shows the scale of investment in this area. Negative values represent the costs of developing a unique technology for delivering drugs across the blood-brain barrier.
Market segment marginality - Neuro
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. Its success depends on its ability to cross the blood-brain barrier. This chart reflects its investment in cutting-edge science compared to other neuroscience companies.
Market marginality as a whole
Denali Therapeutics is a biotech company focused on developing drugs for neurodegenerative diseases such as Alzheimer's and Parkinson's. This overall market profitability chart is irrelevant to the company. Its potential lies in its ability to cross the blood-brain barrier and create breakthrough treatments, changing the lives of millions of patients.
Employees in the company, segment and market as a whole
Number of employees in the company DNLI
Denali Therapeutics is a neuroscience company focused on developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The chart shows the company's growing team of scientists. This growth reflects research progress and partnerships with major pharmaceutical companies.
Share of the company's employees DNLI within the market segment - Neuro
Denali Therapeutics is focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's. This chart shows the percentage of leading neuroscientists and clinicians in this complex field of medicine that the company attracts. It reflects its concentration of unique scientific talent to combat the most severe brain diseases.
Number of employees in the market segment - Neuro
Denali Therapeutics Inc. is a biotech company focused on developing drugs for neurodegenerative diseases such as Parkinson's, Alzheimer's, and ALS. The company uses its platform to cross the blood-brain barrier. This chart shows the growth of employment in the neuroscience research sector, which is attracting increasing investment due to an aging population.
Number of employees in the market as a whole
Denali Therapeutics is a biotech company focused on developing treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's. This is one of the most complex areas in medicine. Their work requires cutting-edge scientific knowledge and creates jobs for elite neuroscience and pharmacology professionals, shaping the economy of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company DNLI (DNLI)
Denali Therapeutics is a neuroscience company developing drugs that can cross the blood-brain barrier. This chart reflects the valuation of breakthrough science. The astronomical market capitalization per employee suggests the market sees enormous potential in their platform for treating Alzheimer's, Parkinson's, and other diseases.
%20of%20the%20company%20DNLI%20(DNLI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-DNLI-DNLI&v=1772548202830 "Chart of market capitalization per employee (in thousands of dollars) of the company DNLI (DNLI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Denali Therapeutics (DNLI) is a biotech company focused on treating neurodegenerative diseases (Alzheimer's, Parkinson's) using blood-brain barrier-crossing technology. This chart shows the industry average cost per employee. It helps estimate the premium the market is paying for their breakthrough scientific platform.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772548203127 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Denali Therapeutics Inc. is a biotech company focused on treating neurodegenerative diseases. This chart shows the market average value of each employee's contribution, highlighting the enormous value the market places on scientific breakthroughs in complex medical fields.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772548203308 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company DNLI (DNLI)
Denali Therapeutics is a biotech company focused on neurodegenerative diseases (Alzheimer's, Parkinson's). They are developing a technology to "transport" drugs across the blood-brain barrier. This graph shows the loss per employee, reflecting the enormous investment in R&D to solve one of the most complex problems in medicine.
%20Chart%20DNLI%20(DNLI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-DNLI-DNLI&v=1772548203583 "Company Profit Per Employee (in thousands of dollars) Chart DNLI (DNLI)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Denali (DNLI) is an R&D biotech (neuro-diseases, BBB "barrier"). This chart shows the benchmark for "Neuro" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. The benchmark reflects the "burn" of money. The entire sector is an R&D race, spending billions on elite scientists in hopes of a future breakthrough.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772548203666 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Denali Therapeutics is a biotech company focused on neurodegenerative diseases (Alzheimer's, Parkinson's). They are developing a technology to "transport" drugs across the blood-brain barrier. This is pure R&D. The graph shows the loss per employee—the cost of their breakthrough, but very expensive, research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772548203722 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee DNLI (DNLI)
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases. This graph shows the long journey from the lab to the patient. For a company solving complex medical problems, it reflects the future potential when a scientific breakthrough turns into a commercially successful product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-DNLI-DNLI&v=1772548203787 "Sales chart per company employee DNLI (DNLI)")
Sales per employee in the market segment - Neuro
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases (Parkinson's, Alzheimer's) by crossing the blood-brain barrier. This is R&D. This chart shows the average revenue per employee in the segment. It serves as a productivity benchmark for commercial pharmaceutical companies.
Sales per employee for the market as a whole
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases (Alzheimer's, Parkinson's). They use "blood-brain barrier transport" technology. The company has no commercial revenue, which is irrelevant. Their value lies in the potential of their R&D team to achieve breakthroughs in the treatment of brain diseases.
Short shares by company, segment and market as a whole
Shares shorted by company DNLI (DNLI)
Denali Therapeutics is a biotech company trying to develop treatments for neurodegenerative diseases (Alzheimer's, Parkinson's) using technology to "transport" drugs across the blood-brain barrier. This is the "holy grail" of neuroscience. The chart shows high skepticism among investors, mindful of the failures in this field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-DNLI-DNLI&v=1772548204551 "Short Shares Chart for the Company DNLI (DNLI)")
Shares shorted by market segment - Neuro
Denali Therapeutics Inc. is a biotech company focused on treating neurodegenerative diseases (Alzheimer's, Parkinson's) by crossing the blood-brain barrier. This chart shows the overall short position in the neuroscience-focused biotech sector. Its rise reflects extreme investor skepticism regarding the success of clinical trials in this most complex area of medicine.
Shares shorted by the overall market
Denali (DNLI) is a biotech focused on neurodegenerative diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs dependent on financing. This pessimism, visible on the chart, threatens the capital needed by DNLI.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator DNLI (DNLI)
Denali Therapeutics is a biotech focused on a challenging task: treating neurodegenerative diseases (Parkinson's, Alzheimer's). Their key technology is transporting drugs across the blood-brain barrier. This chart measures the level of hope. It shows when the stock is overbought on trial news or oversold amid a long R&D cycle.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-DNLI-DNLI&v=1772548205050 "RSI 14 indicator chart for the company's stock DNLI (DNLI)")
RSI 14 Market Segment - Neuro
Denali Therapeutics is a biotech company focused on treating neurodegenerative diseases (Parkinson's, Alzheimer's). Their key technology is a "transport platform" that helps drugs cross the blood-brain barrier. This chart reflects the overall sentiment in the biotech sector and helps assess how the market views this speculative industry.
RSI 14 for the overall market
Denali Therapeutics (DNLI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DNLI (DNLI)
Denali (DNLI) is a biotech company focused on neurodegenerative diseases such as Parkinson's disease. This chart shows the average 12-month forecast. It reflects analysts' confidence in the success of Denali's unique technology for delivering drugs across the blood-brain barrier.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DNLI-DNLI&v=1772548205447 "A chart showing analyst consensus forecasts for the expected stock price. DNLI (DNLI)")
The difference between the consensus estimate and the actual stock price DNLI (DNLI)
Denali is a biotech company focused on neurodegenerative diseases (Alzheimer's, Parkinson's). Its signature feature is its TV technology, which helps drugs penetrate the brain. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in this high-risk R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DNLI-DNLI&v=1772548205583 "A chart showing the difference between the consensus forecast and the actual stock price. DNLI (DNLI)")
Analyst consensus forecast for stock prices by market segment - Neuro
Denali Therapeutics is a biotech company specializing in neurodegenerative diseases (Alzheimer's, Parkinson's). It has developed a technology for delivering drugs across the blood-brain barrier. This chart shows general expectations for the neuroscience sector, reflecting experts' confidence in this delivery platform.
Analysts' consensus forecast for the overall market share price
Denali Therapeutics is a biotech company focused on developing treatments for neurodegenerative diseases (Alzheimer's, Parkinson's) using technology to transport drugs across the blood-brain barrier. This chart shows the overall risk appetite. For Denali, working on the holy grail of neuroscience, overall optimism is essential for funding very expensive and time-consuming research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index DNLI
Denali Therapeutics is a biotech company focused on one of the most challenging areas in medicine: treating neurodegenerative diseases (Alzheimer's, Parkinson's). Their signature feature is their brain-transport (BTS) technology, which delivers drugs across the blood-brain barrier. This chart is an assessment of their unique science. It reflects the market's confidence in their platform and clinical trial data.
AKIMA Market Segment Index - Neuro
Denali (DNLI) is a neuroscience biotech leader; the company is a pioneer in developing Transport Vehicle (TV) technology, which helps drugs cross the blood-brain barrier (for the treatment of Alzheimer's and Parkinson's). This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does Denali's breakthrough (TV) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Denali Therapeutics is a biotech company specializing in the treatment of neurodegenerative diseases (Alzheimer's, Parkinson's) using a unique technology that crosses the blood-brain barrier. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story compares to general economic trends that influence risk appetite.
